Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 18, 2021International Journal of Molecular SciencesOpen Access

Ovarian Cancer Immunotherapy and Personalized Medicine

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSusan MorandSt. Louis Children's HospitalMDMonika DevanaboyinaUniversity of ToledoHSHannah StaatsUniversity of Toledo

Discussion

Loading...

Member takes

Implication

Review evaluates immunotherapy effects on ovarian cancer, indicating biomarkers improve treatment selection.

Key Points

  • This research aims to explore how tumor biomarkers can enhance the effectiveness of immunotherapy in ovarian cancer.
  • Review the current state of immunotherapy in ovarian cancer.
  • Evaluate tumor biomarkers for patient stratification.
  • Discuss novel therapeutics and study designs that involve biomarkers.
  • Identified critical tumor biomarkers like PD-L1 and tumor mutation burden that influence immunotherapy response.
  • Highlight the potential for personalized medicine to improve treatment outcomes.
  • Suggest future research directions focusing on biomarker-driven patient selection.

Cite This Study

Morand et al. (2021) studied this question.

synapsesocial.com/papers/6a08157c4aa57ff4e0e8a0d7https://doi.org/10.3390/ijms22126532
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer2011 · 198 citations
  2. 2Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma2017 · 64 citations
  3. 3Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression2010 · 651 citations